{"id":59856,"date":"2026-03-18T14:15:00","date_gmt":"2026-03-18T06:15:00","guid":{"rendered":"https:\/\/flcube.com\/?p=59856"},"modified":"2026-03-18T14:15:01","modified_gmt":"2026-03-18T06:15:01","slug":"pfizer-reports-positive-fourlight-1-results-for-atirmociclib-cdk4-inhibitor-shows-pfs-benefit-in-post-cdk4-6-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59856","title":{"rendered":"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced <strong>positive topline results<\/strong> from the <strong>Phase II FOURLIGHT-1 study<\/strong>, demonstrating that <strong>atirmociclib in combination with fulvestrant<\/strong> achieved <strong>statistically significant and clinically meaningful improvement in progression-free survival (PFS)<\/strong> versus control regimens in patients with <strong>hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer (MBC)<\/strong> following prior <strong>CDK4\/6 inhibitor therapy<\/strong> \u2013 a population with limited effective options after first-line targeted treatment failure.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone-fourlight-1-phase-ii\">Clinical Milestone \u2013 FOURLIGHT-1 Phase II<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>FOURLIGHT-1 (Phase II)<\/td><\/tr><tr><td><strong>Investigational Arm<\/strong><\/td><td>Atirmociclib + fulvestrant<\/td><\/tr><tr><td><strong>Control Arms<\/strong><\/td><td>Fulvestrant alone; everolimus + exemestane<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>HR+\/HER2- advanced\/metastatic breast cancer<\/td><\/tr><tr><td><strong>Prior Therapy Requirement<\/strong><\/td><td>Previous CDK4\/6 inhibitor treatment<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression-free survival (PFS)<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>Statistically significant and clinically meaningful PFS improvement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Atirmociclib<\/strong> \u2013 <strong>investigational CDK4 inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>CDK4 (cyclin-dependent kinase 4)<\/strong> \u2013 key cell cycle regulator triggering cell division<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Phase II (FOURLIGHT-1); Pfizer independently developed<\/li>\n\n\n\n<li><strong>Therapeutic Hypothesis:<\/strong><\/li>\n\n\n\n<li><strong>CDK4-selective inhibition<\/strong> vs. pan-CDK4\/6 inhibition (palbociclib, ribociclib, abemaciclib)<\/li>\n\n\n\n<li><strong>Differentiated mechanism<\/strong> potentially addressing resistance or intolerance to prior CDK4\/6 inhibitor therapy<\/li>\n\n\n\n<li><strong>Combination with fulvestrant<\/strong> (ER degrader) for endocrine-resistant HR+ breast cancer<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-context-amp-strategic-positioning\">Clinical Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Current Standard<\/th><th>Atirmociclib Position<\/th><\/tr><\/thead><tbody><tr><td><strong>First-Line HR+\/HER2- MBC<\/strong><\/td><td>CDK4\/6 inhibitor + aromatase inhibitor\/fulvestrant<\/td><td>Post-CDK4\/6 progression setting \u2013 high unmet need<\/td><\/tr><tr><td><strong>Post-CDK4\/6 Options<\/strong><\/td><td>Limited: chemotherapy, everolimus-based regimens, single-agent endocrine therapy<\/td><td>Novel CDK4-selective approach with demonstrated PFS benefit<\/td><\/tr><tr><td><strong>Resistance Mechanism<\/strong><\/td><td>CDK4\/6 inhibitor resistance often driven by CDK2 activation, Rb loss, or ESRI mutations<\/td><td>CDK4 selectivity may circumvent certain resistance pathways<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HR+\/HER2- Breast Cancer Market:<\/strong> Global market exceeds <strong>US$20 billion<\/strong> annually; post-CDK4\/6 progression population represents ~50% of advanced HR+ breast cancer patients with median 12-18 months survival after first-line failure \u2013 highest-unmet-need segment driving premium pricing.<\/li>\n\n\n\n<li><strong>CDK4 Selectivity Differentiation:<\/strong> Atirmociclib&#8217;s CDK4-selective profile (vs. CDK4\/6 dual inhibition) may offer improved tolerability (reduced neutropenia, diarrhea) and activity in CDK6-independent resistance mechanisms; FOURLIGHT-1 data supports Phase III trial design with potential for accelerated regulatory pathways.<\/li>\n\n\n\n<li><strong>Pfizer Oncology Pipeline Validation:<\/strong> Atirmociclib represents lead asset in Pfizer&#8217;s targeted oncology portfolio following divestiture of legacy oncology products to Seagen; positive Phase II data supports internal pipeline prioritization and potential combination studies with other Pfizer assets (PD-1 inhibitors, antibody-drug conjugates).<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Post-CDK4\/6 space crowded with emerging therapies (AKT inhibitors, PI3K inhibitors, next-generation SERDs); atirmociclib&#8217;s PFS benefit and Pfizer&#8217;s commercial infrastructure in breast oncology create competitive positioning vs. smaller biotech rivals.<\/li>\n\n\n\n<li><strong>Clinical Catalyst Timeline:<\/strong> Phase III initiation expected H2 2026; potential for <strong>Breakthrough Therapy Designation<\/strong> based on FOURLIGHT-1 magnitude of benefit in defined unmet need population; approval target 2029-2030 assuming positive Phase III.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial expectations for atirmociclib. Actual results may differ due to risks including Phase III trial design challenges, competitive dynamics, and regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59860,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,17,863,309],"class_list":["post-59856","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-results","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating that atirmociclib in combination with fulvestrant achieved statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus control regimens in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer (MBC) following prior CDK4\/6 inhibitor therapy \u2013 a population with limited effective options after first-line targeted treatment failure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59856\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating that atirmociclib in combination with fulvestrant achieved statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus control regimens in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer (MBC) following prior CDK4\/6 inhibitor therapy \u2013 a population with limited effective options after first-line targeted treatment failure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59856\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T06:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-18T06:15:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\\\/6 Breast Cancer\",\"datePublished\":\"2026-03-18T06:15:00+00:00\",\"dateModified\":\"2026-03-18T06:15:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856\"},\"wordCount\":488,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1805.webp\",\"keywords\":[\"Cancer\",\"Clinical trial results\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59856#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59856\",\"name\":\"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\\\/6 Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1805.webp\",\"datePublished\":\"2026-03-18T06:15:00+00:00\",\"dateModified\":\"2026-03-18T06:15:01+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating that atirmociclib in combination with fulvestrant achieved statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus control regimens in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer (MBC) following prior CDK4\\\/6 inhibitor therapy \u2013 a population with limited effective options after first-line targeted treatment failure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59856\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1805.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\\\/6 Breast Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59856#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\\\/6 Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating that atirmociclib in combination with fulvestrant achieved statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus control regimens in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer (MBC) following prior CDK4\/6 inhibitor therapy \u2013 a population with limited effective options after first-line targeted treatment failure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59856","og_locale":"en_US","og_type":"article","og_title":"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer","og_description":"Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating that atirmociclib in combination with fulvestrant achieved statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus control regimens in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer (MBC) following prior CDK4\/6 inhibitor therapy \u2013 a population with limited effective options after first-line targeted treatment failure.","og_url":"https:\/\/flcube.com\/?p=59856","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-18T06:15:00+00:00","article_modified_time":"2026-03-18T06:15:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59856#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59856"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer","datePublished":"2026-03-18T06:15:00+00:00","dateModified":"2026-03-18T06:15:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59856"},"wordCount":488,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59856#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1805.webp","keywords":["Cancer","Clinical trial results","NYSE: PFE","Pfizer"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59856#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59856","url":"https:\/\/flcube.com\/?p=59856","name":"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59856#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59856#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1805.webp","datePublished":"2026-03-18T06:15:00+00:00","dateModified":"2026-03-18T06:15:01+00:00","description":"Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating that atirmociclib in combination with fulvestrant achieved statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus control regimens in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer (MBC) following prior CDK4\/6 inhibitor therapy \u2013 a population with limited effective options after first-line targeted treatment failure.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59856#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59856"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59856#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1805.webp","width":1080,"height":608,"caption":"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59856#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib \u2013 CDK4 Inhibitor Shows PFS Benefit in Post-CDK4\/6 Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1805.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59856"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59856\/revisions"}],"predecessor-version":[{"id":59861,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59856\/revisions\/59861"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59860"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}